Loading...
ROCO
4111
Market cap54mUSD
Oct 08, Last price  
29.00TWD
1D
0.52%
1Q
-4.45%
Jan 2017
30.63%
Name

Chi Sheng Pharma & Biotech Co Ltd

Chart & performance

D1W1MN
ROCO:4111 chart
P/E
10.56
P/S
1.26
EPS
2.75
Div yield, %
3.45%
Shrs. gr., 5y
1.10%
Rev. gr., 5y
7.04%
Revenues
1.38b
+18.11%
1,022,956,000979,359,0001,022,298,0001,143,073,0001,060,864,0001,165,437,0001,376,480,000
Net income
164m
+48.49%
72,450,00059,141,00080,751,000154,006,00068,674,000110,633,000164,280,000
CFO
409m
+91.87%
162,958,000143,530,000139,326,000214,856,00074,519,000213,198,000409,054,000
Dividend
Aug 25, 20261.3 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Chi Sheng Pharma & Biotech Co., Ltd. is a Taiwan-based company actively engaged in the development, production, distribution, and international trade of a diverse range of products. Operating across both domestic and global markets, the company specializes in pharmaceuticals, medical products, cosmetics, health foods, and medical equipment. Its extensive product portfolio covers numerous therapeutic categories, including antibiotics, chemotherapeutic agents, plasma substitutes, amino acid preparations, water nutrients, electrolyte solutions, and vitamins. Additionally, the company provides hepatotropic agents, hormones, adrenal cortical steroids, autonomic nerve agents, antihistamines, antipruritics, antipyretics, analgesics, antitussives, anti-asthmatics, gastro-intestinal preparations, and local anesthetic solutions. Further extending its offerings, Chi Sheng Pharma & Biotech supplies hemodialysis concentrates, peritoneal dialysis solutions, and various other specialized medical items. Beyond medicinal products, the company provides medical devices, fat emulsion products, anesthetics, hemostatic solutions, food products, functional beverages, skincare items, and veterinary medicines. It also offers external solutions such as those for contact lenses, saline, and iodine. The company was founded in 1962 and maintains its headquarters in Hsinchu, Taiwan.

Key people

Dongmao Su
Chairman of the Board, General Manager · since 2003
Wujin Dai
Deputy General Manager-International Business & Management · since 2006
Huizhen Huang
Head of Finance and Accounting, Corporate Governance Officer · since 2023
Yuanqiong Li
Director · since 2024
Rongyao Lin
Director · since 2009
Xiuying Shen Yu
Director
Yaotang Shi
Director · since 2024
Yujun Su
Director · since 2021
Jiajun Su
Director · since 2009
Dongyu Su
Director · since 2003
Mingxun Xie
Director · since 2012
Independent Director · since 2018
Zhenguang Ling
Independent Director
Wenqi Shen
Independent Director
IPO date
Mar 06, 1999
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT